Surfactants, Nanomedicines and Nanocarriers: A Critical Evaluation on Clinical Trials
Advances, perspectives and innovation in drug delivery have increased in recent years; however, there is limited information available regarding the actual presence of surfactants, nanomedicines and nanocarriers in investigational medicinal products submitted as part of a request for authorization o...
Main Authors: | Diego Alejandro Dri, Carlotta Marianecci, Maria Carafa, Elisa Gaucci, Donatella Gramaglia |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/13/3/381 |
Similar Items
-
Critical Analysis and Quality Assessment of Nanomedicines and Nanocarriers in Clinical Trials: Three Years of Activity at the Clinical Trials Office
by: Diego Alejandro Dri, et al.
Published: (2022-07-01) -
Quality Assessment of Investigational Medicinal Products in COVID-19 Clinical Trials: One Year of Activity at the Clinical Trials Office
by: Diego Alejandro Dri, et al.
Published: (2021-12-01) -
Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems
by: Shi Su, et al.
Published: (2020-09-01) -
Editorial: Functionalized Nanocarriers for Theranostics
by: Stefano Leporatti, et al.
Published: (2020-11-01) -
Roles of Surfactants in Oriented Immobilization of Cellulase on Nanocarriers and Multiphase Hydrolysis System
by: Zhiquan Wang, et al.
Published: (2022-03-01)